Clinical Trials
Clinical Trial Detail
Return to search results.
A Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied Agent: NSC#683864, IND#61010) in Combination with Carboplatin and Paclitaxel followed by Temsirolimus (CCI-779) Consolidation as First-Line Therapy in the Treatment of Stage III-IV Clear Cell Carcinoma of the Ovary
| Research Study Number | GOG 0268 | ||
| Principal Investigator | Benjamin Greer, MD | ||
| Phase | II |
|
Keywords
Gynecological Cancer; Ovarian Cancer; Solid Tumors
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Please remember:
- Talk to your health care providers first before making decisions about your health care.
- Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.
- Diseases
& Research
- Treatment
& Support
- About Us
- Labs &
Projects
- Events &
Community Programs
- How You
Can Help Us
The Hutchinson Center's world-renowned scientists are discovering new ways to detect, prevent and treat cancer, HIV/AIDS and many other diseases.
- License Our Discoveries
The Hutchinson Center's world-renowned researchers work together to pursue lifesaving therapies that will help eliminate cancer and related diseases.
The Hutchinson Center's clinical research breakthroughs are delivered to patients through our treatment arm, the Seattle Cancer Care Alliance. This collaboration combines the strengths of the Hutchinson Center, UW Medicine and Seattle Children's.
You can help eliminate cancer and related diseases by attending Hutchinson Center events and participating in our other fundraising and community efforts.
- Divisions
The Hutchinson Center's pioneering researchers push the boundaries of science to find new ways to prevent, detect and treat cancer and related diseases.
Private support is critical to fund new research ideas and innovations, accelerating our ability to make lifesaving discoveries.
